Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ) is very pleased to announce it has entered into a binding term sheet (“Term Sheet” or “Agreement”) to acquire 57% of the outstanding equity of CannabiSendak LTD. (“CannabiSendak”), an Israeli cannabis company founded by iconic Israeli cannabis activist Shlomi Sendak. CannabiSendak intends to establish licensed medical cannabis dispensaries throughout Israel which will provide an unrivalled customer experience, featuring a café, patient consultations and medical professionals on site. CannabiSendak will use HolyCanna as its primary provider of branded cannabis products. HolyCanna is an Israel-based cultivation and nursery license holder which the Company previously entered a binding LOI to acquire a majority equity stake in (see press release dated August 22nd, 2018).

Terms of the LOI are as follows (all figures in USD$):

  • The Company will purchase common shares of CannabiSendak for $300,000 upon closing of the Agreement, and will make contingent payments to CannabiSendak of $200,000 after CannabiSendak reaches clientele of 500 active medical cannabis patients, and additional payments of $250,000 for every incremental 500 active patients CannabiSendak achieves thereafter;
  • The Company will purchase common shares of CannabiSendak from the treasury of CannabiSendak for $200,000, payable in equal tranches of $40,000 over a 5-month period, commencing once CannabiSendak obtains the necessary licenses and approvals for the establishment of dispensaries;
  • The Company will purchase common shares from the treasury of CannabiSendak for $200,000 for the establishment of dispensaries. This consideration will be divided into 4 equal payments of $50,000 each paid every 45 days, commencing the day of signing the Agreement (September 4th, 2018).

Daniel Cohen, CEO of Aura, commented, “We are very pleased to announce this exciting transaction and look forward to working with Shlomi and his team to develop our retail footprint throughout Israel. We believe our cannabis retail strategy will provide significant value creation for our shareholders because of its holistic focus and partnership with industry icon Shlomi Sendak. As a company, we seek to acquire and develop differentiated, value-added cannabis businesses and we believe CannabiSendak further bolsters this objective.”

About Aura Health Inc.

Aura, through its wholly-owned Delaware subsidiary, Green Global Properties Inc. (“Green Global”), owns a 30% interest in four medical marijuana clinics in Las Vegas, Nevada; Mesa, Arizona; Tucson, Arizona and Hollywood, Florida, respectively. Green Global has an option to increase its interest in each such clinic (other than the Nevada clinic) to 51%. Aura currently has an LOI in place to acquire a 54% interest in HolyCanna, an Israel-based cultivation and nursery license holder.

For further information, please contact:

Daniel Cohen, CEO
Aura Health Inc.
(647) 202-1824

David Posner, Director and Chairman

Aura Health Inc.
(647) 985-6727

Caution Regarding Forward-Looking Information:

This news release may contain forward-looking statements and information based on current expectations. Any such forward-looking statements may be identified by words such as “expects”, “anticipates”, “believes”, “projects”, “plans” and similar expressions.  Forward looking information in this news release includes the following statements: (i) expected trading date on the CSE; (ii) management’s belief that the listing on the CSE will increase pool of potential investors and bring other benefits, and (iii) management’s plan to build an international network of vertical integrated businesses in the medical marijuana field. Certain information contained in this press release constitutes forward-looking information, which is information relating to future events or the Corporation’s future performance and which is inherently uncertain. All information other than statements of historical fact may be forward-looking information. Forward-looking information is often, but not always, identified by the use of words such as “seek”, “anticipate”, “budget”, “plan”, “continue”, “estimate”, “expect”, “forecast”, “may”, “will”, “project”, “predict”, “potential”, “targeting”, “intend”, “could”, “might”, “should”, “believe” and similar words or phrases (including negative variations) suggesting future outcomes or statements regarding an outlook. Forward-looking information contained in this press release includes, but is not limited to, final acceptance of the RTO Transaction by CSE and listing of the Corporation’s shares. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information. The Corporation believes the expectations reflected in the forward-looking information are reasonable but no assurance can be given that these expectations will prove to be correct and readers are cautioned not to place undue reliance on forward-looking information contained in this press release. Some of the risks and other factors which could cause results to differ materially from those expressed in the forward-looking information contained in this press release include, but are not limited to: the risks that the RTO Transaction and associated transactions will not be accepted by the CSE, and other risks included in the Listing Statement available at The forward-looking information contained in this press release is made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as otherwise required by law.


Agreement propels development of safe and effective proprietary products and formulations for the emerging psychedelic industry

Optimi Health Corp. (CSE: OPTI) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that effective January 4, 2021, it entered into a lab services agreement with Numinus Wellness Inc. (“Numinus“). Recognized as an early leader in developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), Numinus is aiding Optimi’s mission to further the research and development of Canadian-grown psilocybin-producing mushrooms and related product formulations.

Keep reading... Show less

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), the world’s most innovative cannabis processor, is pleased to provide shareholders with the following corporate update:

Nextleaf Comments on Financial Results from Q1 Financials

Keep reading... Show less

Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”) reported its second quarter results for the period ended December 31, 2020. A complete set of financial statements and Management’s Discussion & Analysis has been filed at All dollar figures are quoted in Canadian dollars.

The second quarter of FY21, saw continued momentum for the Company despite ongoing pandemic related challenges. Net revenue grew 8% to $745,748 from $689,276 versus the same quarter year ago. The Company also saw significant improvement on its bottom line, reducing its net loss by 50% from ($.956) million to ($.481) million, year over year for the quarter, as a result of improved gross margin and cost management efforts. On December 9, 2020, the company announced the closing of the acquisition of substantially all of the assets of Lexaria Canpharm (“Canpharm“), the cannabis products division of Lexaria Biosciences, resulting in the addition of a new B2B Line of Business.

Keep reading... Show less

Royalty Model Provides Access to Early Stage Licenced U.S. Cannabis Companies and Leverage to High-Margin Revenues

FinCanna Capital Corp. (“FinCanna” or the “Company”) (CSE:CALI), a royalty company for the licensed U.S. cannabis industry, is pleased to provide a corporate update further to its recently announced upsized financing of $2 million

Keep reading... Show less

Significant progress made as Numinus-sponsored PRIME study on psilocybin-assisted psychotherapy for opioid, stimulant and/or alcohol use disorders enters pre-implementation stage

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), and Syreon Corporation (Syreon), a global contract research organization with expertise in conducting clinical trials across a broad range of diseases, are pleased to share that significant progress has been made in the single-arm, open-label compassionate access 1 trial of Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders. Currently in the development stage, the PRIME study will assess the efficacy and safety of psilocybin-assisted motivational enhancement therapy.

Keep reading... Show less